Currently, the first-line treatments for advanced or recurrent gastric cancer (AGC) are combination chemotherapy regimens consisting of fluoropyrimidines and platinum, with or without a third agents (trastuzumab if HER2 positive, or a taxane or anthracycline in some regions if HER2 negative) [2, 3], but the prognosis for patients with AGC remains poor, with median overall survival (OS) of 12–15 months in Asia (in Western Countries the median OS is less than 12 months in most studies) [4, 5]. The gene discussed is ERBB2; the disease is gastric cancer.